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ABSTRACT
Objective To evaluate the effectiveness of continuous
glucose monitoring during pregnancy on maternal
glycaemic control, infant birth weight, and risk of
macrosomia in women with type 1 and type 2 diabetes.
Design Prospective, open label randomised controlled
trial.
Setting Two secondary care multidisciplinary obstetric
clinics for diabetes in the United Kingdom.
Participants71womenwithtype1diabetes(n=46)ortype
2 diabetes (n=25) allocated to antenatal care plus
continuous glucose monitoring (n=38) or to standard
antenatal care (n=33).
Intervention Continuous glucose monitoring was used as
aneducationaltooltoinformshareddecisionmakingand
future therapeutic changes at intervals of 4-6 weeks
duringpregnancy.Allotheraspectsofantenatalcarewere
equal between the groups.
Main outcome measures The primary outcome was
maternal glycaemic control during the second and third
trimesters from measurements of HbA1c levels every four
weeks.Secondary outcomes werebirth weightandrisk of
macrosomia using birthweight standard deviation scores
and customised birthweight centiles. Statistical analyses
were done on an intention to treat basis.
Results Women randomised to continuous glucose
monitoring had lower mean HbA1c levels from 32 to
36weeks’gestationcomparedwithwomenrandomisedto
standard antenatal care: 5.8% (SD 0.6) v 6.4% (SD 0.7).
Comparedwithinfantsofmothersinthecontrolarmthose
of mothers in the intervention arm had decreased mean
birthweight standard deviation scores (0.9 v 1.6; effect
size 0.7 SD, 95% confidence interval 0.0 to 1.3),
decreased median customised birthweight centiles (69%
v 93%), and a reduced risk of macrosomia (odds ratio
0.36, 95% confidence interval 0.13 to 0.98).
Conclusion Continuous glucose monitoring during
pregnancy is associated with improved glycaemic control
inthethirdtrimester,lowerbirthweight,andreducedrisk
of macrosomia.
Trial registration Current Controlled Trials
ISRCTN84461581.
INTRODUCTION
Macrosomia,definedasinfantbirthweightonorabove
the90thcentileforsexandgestationalage,remainsthe
commonestcomplicationofpregnancyinwomenwith
diabetes. Nationwide studies from the Netherlands,
UnitedKingdom,andDenmarkconfirmthattheriskof
delivering a large for gestational age, or macrosomic,
infant in women with type 1 diabetes ranges from
48.8% to 62.5%.
1-3 Recent data confirm that women
with type 2 diabetes have an equally high risk of
delivering a macrosomic infant.
45 For mothers with
diabetes, macrosomia leads to increased risk of
perineal lacerations, complications in labour, and
delivery by caesarean section.
6 For the infants the
risks of immediate complications are increased,
including intracranial haemorrhage, shoulder dysto-
cia,neonatalhypoglycaemia,jaundice,andrespiratory
distress
78 as well as the increasingly apparent longer
termhealthrisksofinsulinresistance,obesity,andtype
2 diabetes.
910
Major advances in the management of diabetes
during pregnancy over the past 50 years have
contributed to dramatic reductions in stillbirths and
perinatalmortalitybuthavenothadamajorimpacton
birth weight, with the risk of macrosomia persistently
increased.
11 Prepregnancy care is key to improved
glycaemic control during the first two trimesters but
does not reduce the risk of macrosomia, which we
believe is more strongly associated with hyperglycae-
mia in later gestation.
12 Data from the Netherlands
suggest that near optimal glycaemic control during
early pregnancy (84% of women had a mean HbA1c
level of 7.0% or less) failed to reduce the risk of
macrosomia,presentin48.8%infants.
1Thisprompted
us to consider new strategies, focusing on reducing
postprandialhyperglycaemicspikesduringthesecond
and third trimesters. Observational data suggest a
strong correlation between maternal postprandial
glucose levels in the third trimester with an increased
riskofmacrosomia.
13-17Educationalapproachesincor-
porating additional glucose testing after meals to
improve glycaemic control in late gestation have
shownpotentialtoreducebirthweight.
1819Theoptimal
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pregnancy is, however, unknown, with few women
managing to carry out the 10 daily tests required to
document most glucose excursions.
20
Novel methods of continuous glucose monitoring
provide up to 288 measurements a day.
2122 Detailed
data on the magnitude and duration of glucose
fluctuations, particularly overnight and after meals,
give unique insights into daily glycaemic control,
which are especially valuable during the physiological
changes of pregnancy.
22 Additionally, continuous
glucose monitoring provides patients with visual feed-
backontheconsequencesonglycaemiaoffactorssuch
as diet, exercise, and insulin regimens, which can be
harnessed as a powerful educational tool.
Despite promising pilot evaluations of continuous
glucosemonitoring
2324itisanexpensiveandrelatively
inconvenienttool,promptingtheNationalInstitutefor
Health and Clinical Excellence to call for randomised
studies assessing its efficacy on clinically meaningful
end points.
25 Evidence of effectiveness on long term
glycaemiccontrolordiabetesrelatedmorbidityhasnot
been established, with previous studies limited to the
use of blood glucose or HbA1c levels as surrogate
markers of morbidity from diabetes. We evaluatedthe
effectiveness of antenatal continuous glucose monitor-
ing on maternal glycaemic control and pregnancy
related morbidity—namely, birth weight and risk of
macrosomiaintheoffspringofmotherswithtype1and
type2diabetes.Thepreliminaryphasesofthetrialand
detailed data on glycaemia are described elsewhere.
22
METHODS
We carried out a prospective, open label randomised
controlledtrialcomparingcurrentantenatalcareusing
intermittent self monitoring of glucose levels from
capillary blood obtained using the finger prick
technique (standard care) with antenatal care using
intermittentmonitoringofcapillarybloodglucoseplus
continuous glucose monitoring. The study statistician
used computer generated randomised numbers in
blocksof20,concealedinsealedenvelopes.Wedidnot
use minimisation algorithms. Research nurses trained
in accordance with good clinical practice guidelines
provided the women with their group allocation.
Sample size
We calculated that a sample size of 70 would give 80%
power to detect a 40% reduction in macrosomia at
P=0.05,basedonamacrosomiarateof60%.Fora50%
reduction in risk for macrosomia, a sample size of 70
wouldgive95%power.Previousinterventionalstudies
of postprandial glucose monitoring using capillary
bloodsuggestedthatthiswasfeasible,andinviewofthe
relative expense of continuous glucose monitoring we
hypothesised that a sizeable effect would be required
for it to be integrated into routine antenatal clinical
care.
Setting and participants
From September 2003-6 we carried out a randomised
controlledtrialattwosecondarycarediabeticantenatal
clinics in the United Kingdom. Both were staffed by
two consultant diabetologists; a consultant obstetri-
cian; a midwife, nurse, and dietitian specialising in
diabetes care; and rotating specialist registrars in
obstetrics and diabetes.
Weenrolledpregnantwomenaged16-45withtype1
and type 2 diabetes if they provided written informed
consent and were willing to wear a continuous glucose
monitor. Exclusion criteria were limited to severe
medical or psychological comorbidity, and no women
were excluded. Overall, 71 of 93 (76%) women who
were consecutively approached agreed to participate,
ofwhom46(65%)hadtype1diabetesand25(35%)had
type 2 diabetes. No significant differences were found
between the women who participated or declined in
age,ethnicity,typeordurationofdiabetes,HbA1clevel
or gestational age at booking, attendance for prepreg-
nancy care, and folic acid supplementation. The
participants were therefore representative of women
attendingourdiabetesantenatalclinics.Figure1shows
the reasons for declining participation.
Interventions
Study device
The continuous glucose monitor (CGMS Gold Med-
tronic-MiniMed, Northridge, USA) has a disposable
subcutaneous device for sensing glucose and an
Allocated to standard antenatal care
  without continuous glucose monitor
    (n=33)
Received control intervention (n=33)
Allocated to continuous glucose monitor
  (n=38)
Received intervention (n=36)
Withdrew on or after first visit, citing
  discomfort or dislike of monitor (n=2)
Refused to participate (n=22):
  Not interested (n=6)
  Social issues or problems with transport (n=6)
  Work commitments (n=4)
  Unwilling to wear continuous glucose monitor (n=3)
  Previous stillbirth (n=1)
  Young children (n=1)
  New to area (n=1)
First trimester miscarriage (n=1)
Neonatal death due to Edward’s syndrome
  at 28 weeks’ gestation (n=1)
(31 live singleton infants: 30 healthy
  infants, 1 infant with cardiovascular
  malformation)
Miscarriage (n=1)
Termination (n=1)
Neonatal death (n=1, anencephalic twin)
  with a healthy surviving twin
(38 live infants (33 singletons, 5 twins):
37 healthy infants, 1 infant with trisomy 21)
Women with diabetes assessed for eligibility (n=93)
Follow up
Maternal glycaemic control (n=33)
Birthweight standard deviation score
  (n=30) (healthy singletons)
Birthweight centile and macrosomia (n=30)
  (excluding one live infant with
  cardiovascular malformation)
Maternal glycaemic control (n=38)
Birthweight standard deviation score
  (n=32) (healthy singletons)
Birthweight centile and macrosomia (n=37)
  (excluding one live infant with trisomy 21)
Analysed both when excluding (n=32) and
  when including the five twins, using twin
  specific centiles (n=37)
Analysis
Enrolment (n=71)
Randomised (n=71)
Fig 1 | Progression of women through trial
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by a cable to a lightweight monitor. Interstitial glucose
values in subcutaneous tissues, within a range of 2.2-
22 mmol/l, are measured electrochemically every
10 seconds and an average value is stored every five
minutes,providingupto288measurementsaday.The
system is recalibrated each time a capillary glucose
measurement is entered, and women are advised to
recalibratetheinstrumentatleastfourtimesaday.The
accuracy, reliability, and measurement of glycaemic
control by continuous glucose monitoring has been
improved by recent modification of the sensor,
allowing the device to be worn for up to seven
days.
2627
Study protocol
We offered supplementary continuous glucose mon-
itoring for up to seven days at intervals of 4-6 weeks
between 8 and 32 weeks’ gestation as our experience
suggested that women had greater discomfort using
continuous glucose monitoring in later pregnancy.
22
Insertion of the sensor required an additional hospital
visit (one week before the routine appointment at the
diabetes clinic), and women were offered flexibility in
scheduling both to assist compliance and to allow the
sharing of limited equipment (three monitors per
centre) among participants. Trained research nurses,
withnoclinicalinputatthisvisit,implantedthesensors
into the upper outer buttock. Neither participants nor
professionals had access to the glucose measurements
during sensor use. The women removed the sensors
after 5-7 days unless they experienced pain, discom-
fort, or technical problems, including sensor error.
Afteroneweekthedataweredownloadedtoapersonal
computer using software (Medtronic Com-station,
version 1.7B) provided by the manufacturer.
At their scheduled clinic appointment the women
handed their continuous glucose monitor or glucose
meter in to the diabetes specialist nurse for down-
loadingofthedata.Downloadeddatawereprintedout,
with hard copies given to both the participants and the
health professionals. When possible the women were
giventimetoreviewthedatawiththeirsupportperson
in the waiting area before the clinical review. Women
were asked firstly to note the proportion of time spent
with glucose values within the target range, making
effortstofocusattentiononthepositiveaspectsofeach
continuous or intermittent capillary glucose meter
profile, before proceeding to identify patterns in
hypoglycaemia and hyperglycaemia. They were
advised to note down the likely causes for patterns
thatwereoutofrangeandtosuggestpossiblesolutions
in terms of changes to diet, activity, and insulin dose.
Thiswasdoneinconjunctionwiththeresearchteamat
thefirstvisitandthereafterbytheparticipantsandtheir
supportperson.Thesuggestedtherapeuticadjustments
to diet, exercise, and insulin regimens were then
discussed with the obstetric diabetes team, based on
the combined intermittent capillary glucose and
continuous glucose data for women allocated to
continuous glucose monitoring or the intermittent
capillary glucose data alone for women allocated to
standard antenatal care.
The women were advised to measure blood glucose
levelsatleastseventimesadayandwereprovidedwith
several targets: 3.5-5.5 mmol/l before meals,
<7.8 mmol/l one hour after meals, and <6.7 mmol/l
two hours after meals. The capillaryblood glucose test
results were verified using memory based reflectance
meters.Thewomenwereseenevery2-4weeksforupto
28 weeks, fortnightly until 32 weeks, and weekly
thereafter, with assessments of fetal growth at 28, 32,
and36weeks.Shortactinginsulinanalogueswereused
before meals with intermediate acting insulin, long
acting analogues, or pump therapy. The women with
type 2 diabetes were treated with insulin before
pregnancy or as soon as pregnancy was confirmed.
Care provided at these centres both before and during
pregnancy has been described, with no changes to
routine clinical care during the study period.
12 During
labour and delivery we used intravenous infusions of
glucoseandinsulin,withcapillarybloodglucoselevels
monitored hourly.
Outcome measures
HbA1c levels were measured once every four weeks
and assayed using the aligned methodology (normal
reference range 3.6-5.8%) of the diabetes control and
complications trial in an accredited laboratory partici-
pating in the national external quality assurance
programme. We calculated the birthweight standard
deviation scores for only liveborn singletons using the
British 1990 growth standards.
28 We also calculated
customised birthweight centiles using the open source
gestation network (GROW) program,
29 which uses
Table 1 |Baselinecharacteristicsofpregnantwomenwithpregestationaldiabetesallocatedto
antenatalcarewithcontinuousmonitoringofbloodglucoselevelsortostandardantenatalcare
only(controlgroup).Valuesarenumbers(percentages)unlessstatedotherwise
Characteristics
Continuous glucose
monitoring (n=38)
Standard antenatal
care (n=33)
Mean (SD) age (years) 30.2 (6.3) 32.5 (5.9)
Diabetes type:
Type 1 28 (74) 18 (55)
Type 2 10 (26) 15 (45)
Mean (SD) duration of diabetes (years)* 15.2 (11.0) 10.0 (8.8)
Primiparous 16 (42) 11 (33)
Ethnicity:
White European 34 (89) 29 (88)
Asian 3 (7.9) 3 (9.1)
Other 1 (2.6) 1 (3.0)
Mean (SD) body mass index (kg/m
2) 27.9 (7.0) 28.4 (8.1)
Mean (SD) HbA1c level at booking (%) 7.2 (0.9) 7.4 (1.5)
Mean (SD) gestational age at booking (weeks) 9.4 (2.3) 9.0 (3.0)
Prepregnancy care 24 (63) 18 (55)
Folic acid at booking 33 (87) 27 (82)
Microvascular complication 7 (18.4) 3 (9.7)
Smoker 5 (13.1) 4 (12.1)
*P=0.03.
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sex; and gestational age, with twin standards used for
twin pregnancies.
30 Macrosomia is defined as a birth
weightonorabovethe90thcentile,extremelylargefor
gestationalageasabirthweightonorabovethe97.7th
centile, and small for gestational age as a birth weight
onorbelowthe10thcentile.Weobtainedinformation
on maternal characteristics, insulin doses, and HbA1c
levels from the hospital maternity records.
Statistical analysis
We compared the baseline characteristics of the
women using Fisher exact tests for discrete variables
and t tests for continuous variables. For glycaemic
control, we allocated the HbA1c measurements to
windows of four weeks, and compared the two arms
using t tests. We also used a t test to compare the
standarddeviationscoresforbirthweight.Asaresultof
theheavilyskeweddistributionofbirthweightcentiles,
we compared these between the two arms using the
non-parametric Wilcoxon rank sum test, and we used
Fisherexactteststocomparethepresenceorabsenceof
macrosomia. We used binomial tests for testing
whether the proportion of small for gestational age
infantswasdifferentfrom10%.Allanalysesweredone
on an intention to treat basis, with statistical signifi-
cancesetat5%.Thedatawereanalysedindependently
at the University of Cambridge using S-plus v7.0
(Insightful, Seattle, WA).
We excluded three infants in each group from the
analysesofmeanbirthweight,birthweightcentile,and
birthweight standard deviation score as a result of
miscarriage in the first trimester, neonatal death, and
major malformation (fig 1). For the birthweight
standard deviation scores we included only healthy
singletons (n=62), with twins excluded as no compara-
tive standard exists for twins. We did the analyses for
birthweight centile both with twins (n=67), using the
appropriate centile reference range for twins,
30 and
without twins (n=62).
RESULTS
Overall,38womenwererandomisedtothecontinuous
glucose monitoring intervention and 33 to standard
antenatal care. The mean age of participants was 31.3
(SD 6.1) years, mean body mass index 28.1 (SD 7.4),
and mean duration of diabetes 12.8 (SD 0.3) years
(table 1).AtbookingthemeanHbA1clevelswere7.3%
(SD1.2%)andmeangestationalage9.2(SD2.7)weeks.
Except for duration of diabetes, which was greater in
women in the intervention group, no significant
differences were found between the groups.
Continuous glucose monitoring
The continuous glucose monitor was generally well
tolerated. No skin infections occurred although mild
erythema and inflammation were often seen around
the insertion site of the sensor. Two pregnancies in
intervention women ended prematurely (one miscar-
riage and one termination). The mean number of
periods for continuous glucose monitoring in the
remaining 36 women was 4.2 (range 0-8), with 29 of
thewomen(80%)wearingthemonitoratleastonceper
trimester. One woman who experienced pain after
insertion of the sensor withdrew from the study and
another declined to participate further after the first
continuous glucose profile had been downloaded.
Reasons cited for reduced use of the continuous
glucose monitor were discomfort when wearing the
sensor, transport, and difficulties with bathing.
Glycaemic control
AlthoughtheHbA1clevelwasconsistentlylowerinthe
intervention arm no statistical difference was found in
mean levels between the two groups at booking or
throughout the first two trimesters (fig 2). Differences
betweenthetwoarmsbegantoemergebetween28and
32 weeks’ gestation: mean HbA1c levels in the inter-
vention arm were 6.1% (SD 0.6) compared with 6.4%
(SD0.8)inthecontrolarm,withatrendtowardsbutnot
reaching statistical significance (P=0.1). In later preg-
nancy,at32-36weeks’gestation,afurtherreductionin
HbA1c levels was seen in the intervention arm but no
further reductions in the control arm—a difference in
mean HbA1clevels of 0.6%between groups:5.8% (SD
0.6) in intervention arm compared with 6.4% (SD 0.7)
in control arm (P=0.007).
Pregnancy outcomes
From 71 pregnancies there were 69 living infants
(table 2). Two women miscarried in the first trimester
(one miscarriage in each arm) and one woman had a
termination at 19 weeks as a result of trisomy 21. Two
early neonatal deaths occurred (one in each arm); a
twinpregnancywiththedeathofonetwinat34weeks’
gestation (anencephaly) and another at 28 weeks’
gestation (Edward’s syndrome). Two sets of twins plus
the twin of the anencephalic infant resulted in five
healthy twins (all offspring of women in the inter-
vention arm). Two living infants had malformations,
one cardiovascular (control arm) and one chromoso-
mal (trisomy 21; intervention arm).
Gestation (weeks)
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P=0.007
5.5
Standard antenatal care
Antenatal care plus continuous glucose monitoring
Fig 2 | Mean HbA1c levels every four weeks in women receiving
standard antenatal care (n=33) or antenatal care plus
continuous glucose monitoring (n=38). Vertical lines are
standard deviation at each time point
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with no difference between groups in the mean
gestational age at delivery. No differences were found
in rates of vaginal delivery compared with operative
delivery but a trend was towards reduced emergency
caesareanintheinterventiongroup(P=0.08).Neonatal
morbidity was relatively uncommon, with 17.4%
preterm deliveries (n=12), 21.7% of infants admitted
to neonatal care (n=15), and 11.6% of infants with
hypoglycaemia (n=8). No significant differences were
found between the groups.
Birth weight
Compared with healthy singletons of women in the
control group (n=30), those of women in the inter-
ventiongroup(n=32)haddecreasedmeanbirthweight
standard deviation scores (0.9 v 1.6; effect size 0.7 SD,
95% confidence interval 0.0 to 1.3; P=0.05). Table 2
shows the mean birthweight centiles and median
customised birthweight centiles for 67 of 69 healthy
living infants. The median birthweight centiles were
69% in the intervention group compared with 93% in
thecontrolgroup(P=0.02),withtwinsincludedusinga
twin specific centile reference range.
30 The difference
in birthweight centiles remained significant after
exclusion of the five twins (P=0.04).
In total, 31 of 67 (46%) infants were macrosomic, of
whom 23 were born to mothers with type 1 diabetes
(74%) and eight to mothers with type 2 diabetes (26%).
Thirteen of 37 (35%) infants in the intervention arm
weremacrosomiccomparedwith18of30(60%)inthe
controlarm:oddsratioforreducedriskofmacrosomia
0.36 (95% confidence interval 0.13 to 0.98); P=0.05.
Also fewer extremely large for gestational age infants
were born to mothers in the intervention arm than
controlarm:5/37(13.5%)v9/30(30%).Thisdifference
did not reach statistical significance (P=0.13). The two
largest infants born to mothers in the intervention arm
(5.39 kg and 4.07 kg, with birthweight centiles ≥97.7
and birthweight standard deviation scores >3.5, fig 3)
were born to mothers who withdrew from the inter-
vention (included in the intention to treat analysis).
Oneinfantofamotherintheinterventionarmhada
birthweight standard deviation score below −2 (that is,
below the 95% confidence interval) compared with
infants of mothers in the control arm (fig 3). This girl
was delivered at gestational age 34 weeks and six days
toaprimiparousmother(type1diabetesforfouryears)
withseverepre-eclampsiaandweighed1530g.Onthe
basis of the birthweight centile definition of small for
gestational age (birth weight ≤10th centile) four of 37
(10.8%) infants of women in the intervention arm
(including the girl born to a pre-eclamptic mother)
were small for gestational age compared with 0 of 30
infantsborntowomeninthecontrolarm(P=0.1).One
infant was born to a mother with documented
retinopathy and longstanding type 1 diabetes
(21 years’ duration), and the remaining two to Asian
women with type 2 diabetes with ethnically adjusted
birthweightcentilesexactlyonthe10thcentile,bothof
whomwereclinicallywellanddidnotrequireneonatal
care.Bydefinition,10%ofinfantswouldbeexpectedto
beonorbelowthe10thcentileforbirthweight.Formal
testingshowedthatthenumberofsmallforgestational
age infants in the intervention arm was no different
from that expected (11% v 10%; P=1.0), whereas in the
control arm, if anything fewer babies than expected
were below the 10th centile (0%; P=0.07).
DISCUSSION
Our results suggest that the use of supplementary
continuous glucose monitoring as an educational tool
during pregnancy is associated with improved mater-
nal glycaemic control. The results were clinically and
statistically significant, as the infants of mothers in the
interventionarm(continuousglucosemonitoring)had
a lower birth weightand a reducedrisk ofmacrosomia
than those of mothers in the control arm (standard
antenatal care).
The observed differences in maternal HbA1c levels,
reflecting mean blood glucose levels over the preced-
ing4-6weeks,begantoemergeat28weeksbutdidnot
Table 2 |Pregnancyoutcomeinwomenwithpregestationaldiabetesallocatedtoantenatalcare
pluscontinuousglucosemonitoringortostandardantenatalcareonly(controlgroup).Valuesare
percentages(numbers)unlessstatedotherwise
Variable
Continuous glucose
monitoring (n=38)
Standard antenatal care
(n=33) P value
No of first trimester miscarriages 1 1 1.0
No of terminations 1 0 1.0
Neonatal death* 1 1 1.0
No of live singletons 38 31
No of live singletons with
malformation
1 chromosomal† 1 cardiovascular 1.0
No of women with pre-eclampsia 2 0 0.5
No of twins‡ 5 0 0.5
Delivery mode§:
Vaginal 29 (11) 39 (12) 0.4
Elective caesarean 42 (16) 20 (6) 0.07
Emergency caesarean 29 (11) 43 (13) 0.3
Neonatal morbidity:
Preterm delivery <37 weeks 16 (6) 19 (6) 0.8
Admission to neonatal care unit 24 (9) 19 (6) 0.8
Neonatal hypoglycaemia 8 (3) 17 (5) 0.5
Mean (SD) gestational age at delivery
(weeks)
37.6 (1.3) 37.5 (1.5) 0.8
Mean (SD) birthweight standard
deviation score¶
0.9 (1.0) 1.6 (1.4) 0.05
Mean (SD) birth weight (g)** 3340 (760) 3630 (500) 0.07
Median birthweight centile** 69 93 0.02
Macrosomia (≥90th centile) 35 (13) 60 (18) 0.05
Extremely large for gestational age
(≥97.7th centile)
14 (5) 30 (9) 0.1
Small for gestational age (≤10th
centile)
11 (4) 0 0.1
*Twin pregnancy with death of anencephalic twin and healthy surviving twin.
†Trisomy 21.
‡Two further sets of twins were delivered to mothers in intervention arm resulting in five healthy live twins.
§For comparison between elective and emergency caesarean section rates between groups, P=0.08.
¶Scores calculated only for 62 healthy living singletons (32 in intervention arm, 30 in control arm).
**Calculations were done for 67 of 69 healthy living infants (37 in intervention arm, 30 in control arm), after
excluding one infant from each group as a result of congenital or chromosomal malformation. Twins are
included, with centiles calculated using specific twin standards. Difference in birthweight centiles remained
significant (P=0.04) when twins were excluded.
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gestation. Earlier studies of postprandial finger prick
testing also found better glycaemic control in late
gestation, with improvements in blood glucose levels
during the second and third trimesters and in HbA1c
levels before delivery.
1931 That HbA1c levels do not
improve until the third trimester may reflect the
physiological delay between improved glycaemic
control and clearance of glycated haemoglobin from
the circulation.Alearningcurve also existsforwomen
and health professionals when using continuous
glucose monitoring to optimise lifestyle and therapeu-
ticmanagement,whichinourexperiencetakesseveral
consultations. Indeed, we consistently observed that
improvements in glycaemic profiles were achieved
g r a d u a l l yo v e rp r e g n a n c y ,r a t h e rt h a na f t e ro n e
consultation (data not shown). This emphasises the
importance of using the data from continuous glucose
monitoring as a tool to facilitate patient education and
shared problem solving, and the necessity to reinforce
the benefits over several visits. We have previously
shown the influence of prepregnancy care on early
glycaemic control and hypothesise that initiating
continuous glucose monitoring earlier in pregnancy
—ideally before conception—may help to achieve an
earlier impact on glycaemic control.
Several possible explanations may contribute to the
observed improvements in maternal and neonatal
outcomes. Generally, in standard antenatal care
women measure their blood glucose levels before and
after meals, variably at intervals of one or two hours,
with only the most motivated achieving the minimum
of 10 daily tests required to document fluctuations in
glucose levels.
20 The continuous glucose monitoring
profiles obtained in this study yielded maximal
information about the frequency, magnitude, and
duration of glucose excursions. We believe that the
increased scrutiny of glucose excursions facilitated by
continuous glucose monitoring may have contributed
to increased motivation and compliance with self
management, in particular glucose testing after meals
among women in the intervention group. The visual
impact of continuous glucose monitoring rapidly
focused clinical input towards reducing hyperglycae-
micspikes,whicharelessapparentfromapatientdiary
or glucose meter download but essential if seeking to
limit the transfer of glucose to a fetus. The continuous
glucosemonitoringdataalsoprovidedfeedbackonthe
adequacy of prandial and basal insulin levels, day to
day variability in diet, physical activity, and manage-
ment of hypoglycaemia, with positive feedback to re-
enforceoptimalselfmanagement.Althoughwomenin
the intervention arm had had diabetes for longer than
womeninthecontrolarmthiswouldnotbeexpectedto
contribute to improvement in glycaemic control.
The relative contribution of hyperglycaemia com-
pared with obesity in the development of macrosomia
is controversial
32 but as we adjusted the birthweight
centiles for maternal height and weight, and baseline
maternal body mass indices were similar in both
groups, the observed differences in birth weight are
most likely attributable to the improvements obtained
in glycaemic control. Admittedly, HbA1c levels are
markers of average glycaemic control and do not
provide detailed insight into hyperglycaemic spikes,
implicated in the pathogenesis of macrosomia. The
absence of comparative blinded continuous glucose
data in women who received standard antenatal care
means that we can only speculate on more complex
differences in glycaemia between the groups.
Althoughwecannotfullyexcludethepossibilitythat
tight glycaemic control contributed to fetal growth
restriction, only one infant of a mother in the inter-
ventionarmhadabirthweightstandarddeviationscore
below −2. Four infants of mothers in the intervention
arm and no infants of mothers in the control arm were
born small for gestational age. Ten per cent of infants
would of course be expected to have a birthweight
centile of 10% or less, and four of 37 (11%) is not
significantly different from this prediction (P=0.1).
Indeed, the most strikingly apparent difference in the
number of infants who were small for gestational age
between the two arms is the absolute absence of such
infants of mothers in the control arm, reflecting the
overall trend towards larger babies. Significant neona-
tal morbidity was, however, relatively uncommon in
both groups, with only 17% preterm deliveries and
22% of infants admitted to neonatal care compared
with 37% and 56% of infants nationally.
4
Strengths and limitations of the study
This trial combined recent technological advances in
glucose monitoring with a pragmatic educational
approach, suitable for widespread implementation in
real life clinical settings. It fills a gap identified by the
National Institute for Health and Clinical Excellence
for more research into continuous glucose monitoring
and the need for data not only on interim glucose and
HbA1c levels but also on diabetes related morbidity,
including pregnancy and neonatal outcomes. Further-
more, the randomised design was robust, with high
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Fig3 | Distributionofbirthweightstandarddeviationscoresfor
62 healthy living singletons of mothers in continuous glucose
monitoring arm (n=32) or standard antenatal care arm (n=30).
*Infants of mothers who withdrew from intervention arm
(included in intention to treat analysis). Thick lines indicate
medians and thin lines interquartile ranges
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criteria were applied, such that 76% of women
participated, and despite the moderate inconvenience
of wearing a glucose sensor, 80% of women used
continuous glucose monitoring at least once per
trimester. Only minimal equipment was required,
with three continuous glucose monitors, costing
about £1500 (€1889; $2693) each per centre—one
monitor for every six pregnancies and four glucose
sensors (about £40 each) per pregnancy. Carrying out
thetrialinaroutineclinicalsettingwithjudicioususeof
resources and equipment is key to the generalisability
and replicability of the intervention.
Some limitations should also be considered. Firstly,
the women were predominantly of white European
ethnicity,whichmaylimitapplicabilitytowomenfrom
other cultures and ethnic backgrounds. Secondly,
health professionals were not blinded and therefore
wecannotfullyexcludethepossibilityofbiasinclinical
management. Every effort was, however, made to
standardiseantenatalcontactsbetweengroups,withno
difference in the frequency or duration of clinical
appointments, dietary advice, obstetric input, or fetal
surveillance,andnoclinicalinputduringattachmentof
the continuous glucose sensor. Thirdly, differences in
maternal characteristics, with longer duration of
diabetes in the intervention group, perhaps contrib-
utedtosomeoftheeffectoninfantoutcomes,although
would not explain the improvements in glycaemic
control. Fourthly, the number of women studied is
smallandlargermulticentretrialsarerequiredtoassess
fullythemanyfactorsimplicatedinfetalgrowthandto
document the true costs and benefits of the inter-
vention.
Putting the study in context
Several pilot studies have reported on the potential of
continuous glucose monitoring to assist in adjustment
of the insulin dose during pregnancy, but our
randomised intervention study showed efficacy in
maternal glycaemic control. Outside pregnancy, ran-
domised studies have shown improvements in interim
blood glucose excursions and HbA1c levels associated
with continuous glucose monitoring,
33 but no studies
have shown improvements in diabetes related compli-
cations or morbidity. Our study has filled a gap in the
evidence base, as recognised by the National Institute
for Health and Clinical Excellence,
25 suggesting that
new technologies can be used to reduce the risk of
diabetes related complications in pregnancy.
The observed reductions in birth weight are parti-
cularlyimportantinviewofthewidespreadprevalence
ofmacrosomia,affectingoverhalfofallinfantsbornto
mothers with diabetes in the United Kingdom. Other
advances, including insulin delivery by continuous
subcutaneousinfusion,havefailedtoreducetheriskof
macrosomia. A recent Cochrane review found a
significant increase in birth weight associated with
pump therapy (weighted mean difference 220.56 g).
34
In our experience insulin pumps remain limited by
user input, particularly in the frequency of blood
glucose testing after meals, following physical activity
and correction of hypoglycaemia. As most of the
women in our study were using multiple daily
injections we suggest that further study of continuous
glucose monitoring in women treated by pump is
indicated, to determine the effectiveness in this group.
Implications
Theseresultsshowthatcontinuousglucosemonitoring
during routine antenatal care can provide added
benefits to the pregnancy outcomes for women with
diabetes and their infants. Additional benefits on
intention to treat analysis were a reduction in HbA1c
levels in the third trimester and reduced birth weight
and risk of macrosomia. The consequences of birth
weight are not limited to immediately apparent
deliveryinjuries,whichcanbepreventedbycaesarean
section,asinfantsbornlargeforgestationalagehavean
increasedlongertermriskofinsulinresistance,obesity,
and type 2 diabetes. The widespread prevalence and
lastingeffectsofmaternalhyperglycaemiasuggestthat
thisshouldbeconsideredapotentiallyimportanttarget
for public health strategies, aiming to reduce the
burden of obesity in childhood.
Although rates of macrosomia were reduced in
women using continuous glucose monitoring, they
remain 3.5 times higher than the general maternity
population. This suggests that despite continuous
glucose monitoring helping women to improve aver-
age glycaemic control in late pregnancy, it is still
inadequate for achieving optimal day to day glucose
control and birth weights comparable with the back-
ground population. Perhaps newer generation devices
for real time continuous glucose monitoring will offer
the potential for a more rapid impact on glycaemic
control earlier in pregnancy. Advances in computa-
tional approaches for calculating postprandial glucose
fluxes
35 and the development of closed loop systems
36
may offer additional tools to aim for further reduction
in risk of macrosomia in future decades.
We have shown that supplementary continuous
glucose monitoring provided in a routine clinical
setting leads to better glycaemic control and reduced
riskofmacrosomia.Ifconfirmedbyotherstudiesthese
data have important implications for the antenatal
management of women with diabetes as well as the
immediate and longer term health of their infants.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Continuous glucose monitoring is a potentially beneficial
educational tool, with benefits on glycaemic control
NICE have called for research duringpregnancy, tofocuson
pregnancy complications and infant outcomes
WHAT THIS STUDY ADDS
Continuousglucosemonitoringisassociatedwithimproved
maternal glycaemic control and reduced infant birth weight
and risk of macrosomia
The beneficial effects on pregnancy complications
potentiallyofferlongertermhealthbenefitsfortheinfantsof
mothers with diabetes
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